Neurotech International (ASX: NTI) has announced the publication of its Phase 1/2 clinical trial results for Rett syndrome in the peer-reviewed scientific journal, Journal of Paediatrics and Child Health.
The publication, Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study, provides detailed results from the open-label clinical trial evaluating NTI164, Neurotech’s novel full-spectrum medicinal cannabis plant extract.
The study assessed NTI164's impact across multiple clinical domains relevant to Rett syndrome.
The company stated that key findings include that NTI164 was well-tolerated. Clinical improvements were also observed across key symptom areas relevant to Rett syndrome, and NTI164 demonstrated potential broader therapeutic benefits, including improvements in neurological, behavioural, and functional measures.
The authors concluded that the results provide compelling evidence for NTI164 as a potential therapy for Rett Syndrome.
Neurotech’s Managing Director and CEO, Dr Anthony Filippis, said, "This publication in a respected peer-reviewed journal further underscores the scientific and clinical merit of NTI164. It represents an important step forward in our ongoing efforts to provide novel therapeutic options for Rett syndrome and other paediatric neurological conditions."